| Literature DB >> 28979303 |
Hamid Reza Akbari Hasanjani1, Mahmoud Reza Sohrabi1.
Abstract
Simultaneous spectrophotometric estimation of Fluoxetine and Sertraline in tablets were performed using UV-Vis spectroscopic and Artificial Neural Networks (ANN). Absorption spectra of two components were recorded in 200-300 nm wavelengths region with an interval of 1 nm. The calibration models were thoroughly evaluated at several concentration levels using the spectra of synthetic binary mixture (prepared using orthogonal design). Three layers feed-forward neural networks using the back-propagation algorithm (B.P) has been employed for building and testing models. Several parameters such as the number of neurons in the hidden layer, learning rate and the number of epochs were optimized. The Relative Standard Deviation (RSD) for each component in real sample was calculated as 1.06 and 1.33 for Fluoxetine and Sertraline, respectively. The results showed a very good agreement between true values and predicted concentration values. The proposed procedure is a simple, precise and convenient method for the determination of Fluoxetine and Sertraline in commercial tablets.Entities:
Keywords: Artificial Neural Networks (ANN); Chemometrics; Fluoxetine; Sertraline; Spectrophotometric
Year: 2017 PMID: 28979303 PMCID: PMC5603857
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Figure 1The structures of fluoxetine HCl (A) and sertraline HCl (B).
Figure 2Absorbance spectra of fluoxetine 20 𝜇𝑔𝑚𝐿−1 (I) and sertraline 20 𝜇𝑔𝑚𝐿−1(II) in ethanol
Composition of the calibration sample
|
|
| |
|---|---|---|
|
|
| |
| 1 | 2 | 1 |
| 2 | 2 | 4 |
| 3 | 2 | 6 |
| 4 | 2 | 8 |
| 5 | 2 | 0 |
| 6 | 4 | 2 |
| 7 | 4 | 0 |
| 8 | 4 | 8 |
| 9 | 4 | 6 |
| 10 | 4 | 4 |
| 11 | 6 | 1 |
| 12 | 6 | 4 |
| 13 | 6 | 8 |
| 14 | 6 | 0 |
| 15 | 6 | 2 |
| 16 | 8 | 6 |
| 17 | 8 | 4 |
| 18 | 8 | 0 |
| 19 | 8 | 3 |
| 20 | 8 | 8 |
Figure 3The relationship between numbers of nodes in the hidden layer versus SSE for Fluoxetine (I) and Sertraline (II
Composition of validation set, their prediction by the ANN model and statistical parameters for the system.
|
|
|
|
| |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| 1 | 2 | 2 | 2.20 | 1.80 | 110.00 | 90.00 |
| 2 | 3 | 3 | 2.91 | 3.30 | 97.00 | 110.00 |
| 3 | 4 | 6 | 3.82 | 6.01 | 95.50 | 100.16 |
| 4 | 5 | 8 | 5.06 | 8.50 | 101.20 | 106.25 |
| 5 | 6 | 9 | 5.70 | 9.34 | 95.00 | 103.77 |
| 6 | 7 | 10 | 6.66 | 10.14 | 95.14 | 101.40 |
| 7 | 8 | 12 | 7.60 | 11.45 | 95.00 | 95.41 |
| 8 | 10 | 14 | 9.86 | 14.24 | 98.60 | 101.41 |
| Mean Recovery (%) | 98.43 | 101.08 | ||||
| RMSE | 0.24 | 0.33 | ||||
Figure 4Plots of predicted concentration versus actual concentration for Fluoxetine (FLX) and Sertraline (SRT) by ANN (μgmL−1
Figure 5Error performance for tarining of ANN with actual inputs
Determination of Fluoxetine and Sertraline by using ANN model in pharmaceutical formulation
|
|
|
| ||
|---|---|---|---|---|
|
|
|
|
| |
| 1 | 20 | 19.31 | 100 | 101.17 |
| 2 | 20 | 21.22 | 100 | 99.49 |
| 3 | 20 | 19.44 | 100 | 98.62 |
| Mean Recovery (%) | 99.95 | 99.76 | ||
| RMSE | 0.29 | 0.42 | ||
| RSD | 1.06 | 1.33 | ||
Fig.6Absorbance spectra of fluoxetine 20 (I) and sertraline 20(II) in ethanol
Determination of fluoxetine and sertraline in urine using ANN model .
|
|
|
|
|
|---|---|---|---|
| Urine sample 1 | 1.50 | 1.42 | 94.7 |
| Urine sample 2 | 3 | 3.31 | 94.6 |
The ANOVA results by applying the proposed method to the real sample
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Between Groups | ||||||
| Fluoxetine | 0.1089 | 1 | 0.1089 | 0.137483 | 0.746386 | 18.51282 |
| Sertraline | 0.893025 | 1 | 0.893025 | 4.719382 | 0.161935 | 18.51282 |
| Within Groups | ||||||
| Fluoxetine | 1.5842 | 2 | 0.7921 | |||
| Sertraline | 0.37845 | 2 | 0.189225 | |||
| Total | ||||||
| Fluoxetine | 1.6931 | 3 | ||||
| Sertraline | 1.271475 | 3 | ||||
ss, sum of squares; df, degree of freedom; MS, mean squares.